Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Transient Ischaemic Attack (TIA) in 8 Major Markets
Transient ischaemic attack (TIA), also known as a mini or minor stroke, is an acute episode that results in a temporary loss of neurologic function. Similar to strokes, they are caused by the disruption of cerebral blood flow which can happen as a result of either partial or total occlusion or stenosis of a vessel. Unlike a stroke the symptoms of a TIA can resolve themselves usually between a few minutes and 24 hours.
This report provides the current incident population for TIA disease across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of TIA have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for TIA include:
• Atherosclerosis
• Coronary artery disease
• Aortic arch atheroma
• Atrial fibrillation
• Dyslipidaemias
• Diabetes
• Ischaemic heart disease
• Neurological conditions
o E.g. paresis, aphasia
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global TIAs market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of TIA and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on TIAs incident population.
• Identify sub-populations within TIA which require treatment.
• Gain an understanding of the specific markets that have the largest number of TIA patients.
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions/Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Incidence for Transient Ischaemic Attack
• Features of TIA Patients
o Aetiology and Classification of TIA
o Vascular Territory and Stenosis of TIA
o Cardiac Conditions Associated with TIA
o Neurological Conditions of TIA
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables & Figures
• ABCD2 Risk Stratification Scores for Stroke
• Incidence of TIA, total (000s)
• Incidence of TIA, males (000s)
• Incidence of TIA, females (000s)
• Dichotomised risk factors in TIA patients, total (000s)
• Aetiology of TIA in patients, total (000s)
• Vascular territory in TIA patients, total (000s)
• ?50% stenosis in vertebrobasilar TIA patients, total (000s)
• ?50% stenosis in carotid TIA patients, total (000s)
• Aortic arch atheroma (AAA) in TIA patients, total (000s)
• AAA severity in TIA patients, total (000s)
• Hypertension in TIA patients, total (000s)
• Ischaemic heart disease in TIA patients, total (000s)
• Atrial fibrillation in TIA patients, total (000s)
• Clinical neurological symptoms in TIA patients, total (000s)
• Unilateral paresis in TIA patients with neurological conditions, total (000s)
• Dysarthia in TIA patients with neurological conditions, total (000s)
• Unilateral sensory loss in TIA patients with neurological conditions, total (000s)
• Aphasia in TIA patients with neurological conditions, total (000s)
• Abbreviations and acronyms used in the Report
• USA Incidence of TIA by 5-yr age cohort, males (000s)
• USA Incidence of TIA by 5-yr age cohort, females (000s)
• France Incidence of TIA by 5-yr age cohort, males (000s)
• France Incidence of TIA by 5-yr age cohort, females (000s)
• Germany Incidence of TIA by 5-yr age cohort, males (000s)
• Germany Incidence of TIA by 5-yr age cohort, females (000s)
• Italy Incidence of TIA by 5-yr age cohort, males (000s)
• Italy Incidence of TIA by 5-yr age cohort, females (000s)
• Spain Incidence of TIA by 5-yr age cohort, males (000s)
• Spain Incidence of TIA by 5-yr age cohort, females (000s)
• United Kingdom Incidence of TIA by 5-yr age cohort, males (000s)
• United Kingdom Incidence of TIA by 5-yr age cohort, females (000s)
• Brazil Incidence of TIA by 5-yr age cohort, males (000s)
• Brazil Incidence of TIA by 5-yr age cohort, females (000s)
• Japan Incidence of TIA by 5-yr age cohort, males (000s)
• Japan Incidence of TIA by 5-yr age cohort, females (000s)
